Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Amitriptyline Hydrochloride Tablets USP in strengths of 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg. The drug is used to treat depression and will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.
The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
